5Brown B G, Zhao X Q. Importance of endothelial function in mediating the benefits of lipid lowering therapy [J]. Am J Cardiol, 1998,82 ( 1 ) : 49T.
6Kinlay S, Schwartz G G, Olsson A G, et al. Biological mechanism for the clinical success of lipid-lowerlng in coronary artery disease and the use of surrogate endpoints[J]. Curr Opin Lipidol, 1996,7 (4) : 389.
7Becker R C, Cannon C P, Bovill E G, et al. Prognostic Value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction[J]. Am J Cardiol, 1996,78(2):142.
8Erust E, Resch K L. Fibrincugess as a cardiovascular risk factor:A metaanalyais and review of the literature[J]. Am Intern Med,1993,118(8):956.
9Crouse J R, Byington R P, Hoen H M, et al. Reductase inhibitor monotherapy and stroke prevention[J]. Arch Intern Med, 1997,157(11):1305.
10Pedersen T R, Kjekshus J, Pyorala K, et al. Efleet of simrastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study(4s) [J]. Am J Cardio, 1998,81 (3) :333.
